CIK 0001818382 · Non-accelerated filer<br>Smaller reporting company
Humacyte, Inc.
Sign in to watch- Ticker
- HUMA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 851763759
- Phone
- 919-313-9633
- Business address
- 2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM, NC, 27713
- Former names
- Alpha Healthcare Acquisition Corp.
- Open-market buys, last 90 days
- $30,370
- in 3 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$30,370. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-08-29 | Niklason Laura E President, CEO and Director | Purchase | +1,222 | $6.55 | $8K | 242,054 |
| 2024-08-29 | Dougan Brady W Director | Purchase | +1,222 | $6.55 | $8K | 242,054 |
| 2024-08-29 | Dougan Brady W Director | Sale | −352,112 | $6.35 | $2.2M | 3,677,262 |
| 2024-08-29 | Niklason Laura E President, CEO and Director | Sale | −352,112 | $6.35 | $2.2M | 3,677,262 |
| 2024-08-28 | Dougan Brady W Director | Sale | −277,090 | $6.47 | $1.8M | 4,029,374 |
| 2024-08-28 | Niklason Laura E President, CEO and Director | Sale | −277,090 | $6.47 | $1.8M | 4,029,374 |
| 2024-08-27 | Dougan Brady W Director | Sale | −252,676 | $6.71 | $1.7M | 4,306,464 |
| 2024-08-27 | Niklason Laura E President, CEO and Director | Sale | −252,676 | $6.71 | $1.7M | 4,306,464 |
| 2024-08-27 | Sander Dale A. CFO and Chief Corp. Deve. Off. | Option exercise | +39,389 | $2.56 | $101K | 41,389 |
| 2024-08-27 | Sander Dale A. CFO and Chief Corp. Deve. Off. | Sale | −39,389 | $6.68 | $263K | 2,000 |
| 2024-08-27 | Sander Dale A. CFO and Chief Corp. Deve. Off. | Option exercise · Stock Options (right to buy) | −39,389 | 0 | ||
| 2024-08-15 | Constantino Michael T. Director | Purchase | +3,100 | $6.29 | $19K | 12,350 |
| 2024-06-14 | Sebelius Kathleen Director | Option exercise | +39,389 | $2.56 | $101K | 39,389 |
| 2024-06-14 | Sebelius Kathleen Director | Option exercise · Stock Options (right to buy) | −39,389 | 0 | ||
| 2024-06-13 | Sebelius Kathleen Director | Grant or award · Stock Options (right to buy) | +50,000 | 50,000 | ||
| 2024-06-13 | Windham-Bannister Susan Richards Director | Grant or award · Stock Options (right to buy) | +50,000 | 50,000 | ||
| 2024-06-13 | Wallace Max N. Director | Grant or award · Stock Options (right to buy) | +50,000 | 50,000 | ||
| 2024-06-13 | Seimetz Diane Director | Grant or award · Stock Options (right to buy) | +50,000 | 50,000 | ||
| 2024-06-13 | Pope Todd Director | Grant or award · Stock Options (right to buy) | +50,000 | 50,000 | ||
| 2024-06-13 | Niklason Laura E President, CEO and Director | Grant or award · Stock Options (right to buy) | +50,000 | 50,000 |
Page 5 of 17 · 330 trades